Logo image
Longitudinal analysis of contrast acuity in Friedreich ataxia
Journal article   Open access   Peer reviewed

Longitudinal analysis of contrast acuity in Friedreich ataxia

Ali G Hamedani, Lauren A Hauser, Susan Perlman, Katherine Mathews, George R Wilmot, Theresa Zesiewicz, S H Subramony, Tetsuo Ashizawa, Martin B Delatycki, Alicia Brocht, …
Neurology. Genetics, Vol.4(4), pp.e250-e250
08/2018
DOI: 10.1212/NXG.0000000000000250
PMCID: PMC6066362
PMID: 30065952
url
https://doi.org/10.1212/NXG.0000000000000250View
Published (Version of record) Open Access

Abstract

To determine the natural history of contrast acuity in Friedreich ataxia. In the Friedreich Ataxia-Clinical Outcome Measures Study, participants (n = 764) underwent binocular high- and low-contrast visual acuity testing at annual study visits. Mixed-effects linear regression was used to model visual acuity as a function of time, with random intercepts and slopes to account for intraindividual correlation of repeated measurements. A time-varying covariate was used to adjust for diabetes, and interaction terms were used to assess for effect modification by GAA repeat length, disease duration, and other variables. Across a median of 4.4 years of follow-up, visual acuity decreased significantly at 100% contrast (-0.37 letters/y, 95% confidence interval [CI]: -0.52 to -0.21), 2.5% contrast (-0.81 letters/year, 95% CI: -0.99 to -0.65), and 1.25% contrast (-1.12 letters/y, 95% CI: -1.29 to -0.96 letters/year). There was a significant interaction between time and GAA repeat length such that the rate of decrease in visual acuity was greater for patients with higher GAA repeat lengths at 2.5% contrast ( = 0.018) and 1.25% contrast ( = 0.043) but not 100% contrast. There was no effect modification by age at onset after adjusting for GAA repeat length. Low-contrast visual acuity decreases linearly over time in Friedreich ataxia, and the rate of decrease is greater at higher GAA repeat lengths. Contrast sensitivity has the potential to serve as a biomarker and surrogate outcome in future studies of Friedreich ataxia.

Details

Metrics

Logo image